Drug produced by Regeneron and Roche Laboratories approved to treat and prevent Covid-19 in UK Photo: Pixabay
The United Kingdom’s Medicines Regulatory Agency (MHRA, its acronym in English) approved on Friday (20) the first drug to prevent and treat Covid-19 in the country. Ronapreve, developed by the pharmaceutical companies Roche and Regeneron, is a treatment with monoclonal antibodies. Proteins produced in the lab act like natural human antibodies in the immune system.
According to the MHRA, the drug is given by injection and works on the lining of the respiratory system, preventing the coronavirus from accessing cells in the respiratory system. Ronapreve clinical trials were conducted last year, showing that the product is effective in preventing infection, improving symptoms of severe Covid-19, and also reducing the risk of hospitalization for the disease.
“This treatment will be an important addition to our arsenal in the fight against Covid-19,” said UK Health Secretary Sajid Javid. “We are now working with the NHS [sistema de saúde britânico] and medical specialists to ensure this treatment can be implemented for NHS patients as quickly as possible. “
Ronapreve was administered to former US President Donald Trump when he contracted the disease last year. The treatment has also been urgently approved by the United States and Anvisa for some cases.